The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus

The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus

Past studies have confirmed that glucagon-like peptide 1 (GLP-1) receptor agonists can improve renal outcomes in patients with type 2 diabetes mellitus (DM). This study aimed to evaluate whether dipeptidyl peptidase 4 (DPP-4) inhibitors, which elevate GLP-1 levels, also have similar effects on renal...

Full description

Bibliographic Details
Main Authors:	Wan-Chia Hsu, Chun-Sheng Lin, Jung-Fu Chen, Chih-Min Chang
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Journal of Clinical Medicine
Subjects:	diabetic kidney disease DPP-4 inhibitor eGFR renal function type 2 diabetes mellitus
Online Access:	https://www.mdpi.com/2077-0383/11/9/2653

Similar Items

Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
by: Rodrigo Daza-Arnedo, et al.
Published: (2021-11-01)

Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
by: Faraha Ahmed, et al.
Published: (2023-12-01)

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
by: Badrud Duza Mohammad, et al.
Published: (2022-09-01)

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)
by: E. A. Ortenberg, et al.
Published: (2022-06-01)

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
by: Frederich Robert, et al.
Published: (2012-07-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
by: Akifumi Matsumoto, et al.
Published: (2023-12-01)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
by: Kaisa Tasanen, et al.
Published: (2019-06-01)

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
by: Rahim K, et al.
Published: (2024-03-01)

Correlation study of renal function indices with diabetic peripheral neuropathy and diabetic retinopathy in T2DM patients with normal renal function
by: Yue-Yang Zhang, et al.
Published: (2023-12-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022-09-01)

Effect of dipeptidyl peptidase 4 inhibitors on cardiovascular events in type-2 diabetes patients with renal impairment: A systematic review and meta-analysis
by: Maneesha Khalse, et al.
Published: (2020-01-01)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-12-01)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
by: Xu Liu, et al.
Published: (2021-09-01)

Correlation of renal function indicators and vascular damage in T2DM patients with normal renal function
by: Yue-Yang Zhang, et al.
Published: (2023-12-01)

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review
by: Iuliia G. Samoilova, et al.
Published: (2024-01-01)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022-11-01)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
by: Munehiro Kitada, et al.
Published: (2019-05-01)

SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

An Integrated In Silico and In Vitro Assays of Dipeptidyl Peptidase-4 and α-Glucosidase Inhibition by Stellasterol from <i>Ganoderma australe</i>
by: Krisyanti Budipramana, et al.
Published: (2019-08-01)

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand
by: Permsuwan U, et al.
Published: (2016-09-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus
by: I. V. Glinkina, et al.
Published: (2021-05-01)

Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection
by: Tzu-I Chen, et al.
Published: (2023-02-01)

Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
by: Eugene Yu-Chuan Kang, et al.
Published: (2021-06-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)

Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
by: Woh Yon Mak,, et al.
Published: (2020-12-01)

Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks
by: Sanbao Chai, et al.
Published: (2022-07-01)

Four missense genetic variants in CUBN are associated with higher levels of eGFR in non-diabetes but not in diabetes mellitus or its subtypes: A genetic association study in Europeans
by: Nicoline Uglebjerg, et al.
Published: (2023-02-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01)

Evaluation of Vascular Endothelial Function in Children with Type 1 Diabetes Mellitus
by: Karolina Nocuń-Wasilewska, et al.
Published: (2021-10-01)

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
by: Jaehyun Bae, et al.
Published: (2016-03-01)

The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus
by: Alexandra Katsimardou, et al.
Published: (2023-05-01)

Evaluation of Hypoglycaemic Effects of Dipeptidyl Peptidase–4 Inhibitors and Biguanide on Type-2 Diabetic subjects: A six months trial
by: Naghma Ms., et al.
Published: (2020-12-01)

Dipeptidyl peptidase IV inhibitors derived from a mangrove flora Rhizophora mucronata: An in silico approach
by: Selvaraj Gurudeeban, et al.
Published: (2012-10-01)

Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)
by: Ivan O. Maslov, et al.
Published: (2022-02-01)